Biotech · Public company · South San Francisco, CA, US

Nkarta, Inc.

Ticker NKTX · SEC CIK 0001787400

Track this companyFree. Adds Nkarta, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials55 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

CyclophosphamidePhase 2 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
Fludarabine, CyclophosphamidePhase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
NKX019Phase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
NKX019Phase 2 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
NKX019Phase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
NKX101 - CAR NK cell therapyPhase 1 · Relapsed/Refractory AMLClinicalTrials.gov · fetched Nov 12, 2026

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)PHASE1_PHASE2 · RECRUITING · started Nov 4, 2024ClinicalTrials.gov NCT06733935 · fetched Nov 12, 2026
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusPHASE1 · ENROLLING_BY_INVITATION · started Jul 1, 2024ClinicalTrials.gov NCT06518668 · fetched Nov 12, 2026
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)PHASE1_PHASE2 · RECRUITING · started Jun 13, 2024ClinicalTrials.gov NCT06557265 · fetched Nov 12, 2026
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 20, 2021ClinicalTrials.gov NCT05020678 · fetched Nov 12, 2026
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 21, 2020ClinicalTrials.gov NCT04623944 · fetched Nov 12, 2026